Analysis of the correlation between Guillain-Barré and post-COVID-19 syndromes

Matheus Lopes Martins; Sabrina Carvalho Melo; Amanda de Brito Silva; Luan Kelves Miranda de Souza

doi:10.31686/ijier.vol10.iss12.4003

Authors

Matheus Lopes Martins https://orcid.org/0000-0001-7083-2943
Sabrina Carvalho Melo https://orcid.org/0000-0001-6605-3381
Amanda de Brito Silva https://orcid.org/0000-0002-7248-7343
Luan Kelves Miranda de Souza https://orcid.org/0000-0002-8019-4022

DOI:

https://doi.org/10.31686/ijier.vol10.iss12.4003

Keywords:

Guillain-Barré syndrome, Demyelinating Diseases, COVID-19

Abstract

OBJECTIVE: To correlate Guillain-Barré as a consequence of the Post-COVID-19 syndrome, evaluating the pathophysiological, immunogenic and epidemiological mechanisms. METHODOLOGY: A systematic review was carried out, with secondary data, using articles published in the following databases: Latin American Caribbean Literature on Science and Health (LILACS), Scientific Electronic Library (ScIELO) and Pubmed; using the descriptors: Guillain-Barré syndrome; Demyelinating Diseases and COVID-19, using the Boolean operator “AND”, swapping between them. RESULTS AND DISCUSSION: According to Abu-Rumeileh et al. (2021), patients with COVID-19, even if asymptomatic, were more likely to develop GBS, with a predominance of the male population, in the classic sensorimotor form and in acute inflammatory demyelinating polyneuropathy, with an increase in pediatric cases also being observed, due to of the wide age range of Sars-Cov-2. The post-infection immune-mediated pathophysiological mechanism observed some predisposing factors, namely: neurological symptoms after Sars-Cov-2 infection, improvement of the clinical picture of GBS with immunomodulators and absence of viral RNA in the cerebrospinal fluid. CONCLUSION: Guillain-Barré Syndrome consists of an immune-mediated neuromuscular condition usually subsequent to an infectious process, which triggers an inflammatory response followed by a molecular mimicry that causes an autoimmune response in the individual's peripheral nervous system. Although there is no consensus in the scientific community regarding the causal relationship between COVID-19 and GBS, it is believed that infection with the new coronavirus precipitates an immune-mediated reaction that triggers this neuromuscular condition characterized by progressive, symmetrical and ascending weakness, in addition to areflexia.

Downloads

Download data is not yet available.

Author Biographies

Matheus Lopes Martins

Faculty of Human
Sabrina Carvalho Melo

Faculty of Human
Amanda de Brito Silva

Faculty of Human
Luan Kelves Miranda de Souza

Faculty of Human

References

Abu-Rumeileh, S., Abdelhak, A., Foschi, M., Tumani, H., & Otto, M. (2020). Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Journal of Neurology, 269(4). https://doi.org/10.1007/s00415-020-10124-x DOI: https://doi.org/10.1007/s00415-020-10124-x

Aladawi, M., Elfil, M., Abu-Esheh, B., Abu Jazar, D., Armouti, A., Bayoumi, A., & Piccione, E. (2022). Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, 49(1), 38–48. https://doi.org/10.1017/cjn.2021.102 DOI: https://doi.org/10.1017/cjn.2021.102

Caress, J. B., Castoro, R. J., Simmons, Z., Scelsa, S. N., Lewis, R. A., Ahlawat, A., & Narayanaswami, P. (2020). COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & Nerve, 62(4). https://doi.org/10.1002/mus.27024 DOI: https://doi.org/10.1002/mus.27024

Collantes, M. E. V., Espiritu, A. I., Sy, M. C. C., Anlacan, V. M. M., & Jamora, R. D. G. (2020). Neurological manifestations in COVID-19 infection: A systematic review and meta-analysis. Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques, 1–26. https://doi.org/10.1017/cjn.2020.146 DOI: https://doi.org/10.1017/cjn.2020.146

D, V., Sharma, A., Kumar, A., & Flora, S. J. S. (2021). Neurological Manifestations in COVID-19 Patients: A Meta-Analysis. ACS Chemical Neuroscience, 12(15), acschemneuro.1c00353. https://doi.org/10.1021/acschemneuro.1c00353 DOI: https://doi.org/10.1021/acschemneuro.1c00353

Dalakas, M. C. (2020). Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurology - Neuroimmunology Neuroinflammation, 7(5). https://doi.org/10.1212/NXI.0000000000000781 DOI: https://doi.org/10.1212/NXI.0000000000000781

De Sanctis, P., Doneddu, P. E., Viganò, L., Selmi, C., & Nobile‐Orazio, E. (2020). Guillain Barré Syndrome associated with SARS‐CoV‐2 infection. A Systematic Review. European Journal of Neurology. https://doi.org/10.1111/ene.14462 DOI: https://doi.org/10.1111/ene.14462

FINSTERER, J., SCORZA, F. A., SCORZA, C. A., & FIORINI, A. C. (2021). Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit. Arquivos de Neuro-Psiquiatria, 79. https://doi.org/10.1590/0004-282x-anp-2021-0030 DOI: https://doi.org/10.1590/0004-282x-anp-2021-0030

Freire, M., Andrade, A., Sopeña, B., & Lopez-Rodriguez, M. (2021). Guillain Barré syndrome associated with COVID-19- lessons learned about its pathogenesis during the first year of the pandemic, a systematic review. Autoimmunity Reviews, 20(8), 102875. https://doi.org/10.1016/j.autrev.2021.102875 DOI: https://doi.org/10.1016/j.autrev.2021.102875

Gittermann, L. M. T., Feris, S. N. V., & Giacoman, A. von O. (2020). Relation between COVID-19 and Guillain-Barré syndrome in adults: a systematic review. Neurología (English Edition), 35(9), 646–654. https://doi.org/10.1016/j.nrleng.2020.07.005 DOI: https://doi.org/10.1016/j.nrleng.2020.07.005

Hasan, I., Saif-Ur-Rahman, K. M., Hayat, S., Papri, N., Jahan, I., Azam, R., Ara, G., & Islam, Z. (2020). Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis. Journal of the Peripheral Nervous System: JPNS, 25(4), 335–343. https://doi.org/10.1111/jns.12419 DOI: https://doi.org/10.1111/jns.12419

Koike, H., Chiba, A., & Katsuno, M. (2021). Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A Review. Neurology and Therapy, 25(2). https://doi.org/10.1007/s40120-021-00261-4 DOI: https://doi.org/10.1007/s40120-021-00261-4

Kulikowska, J., Kulczyńska-Przybik, A., Mroczko, B., & Kułakowska, A. (2021). The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis—A Literature Review. International Journal of Molecular Sciences, 22(11), 5894. https://doi.org/10.3390/ijms22115894 DOI: https://doi.org/10.3390/ijms22115894

Mohamadian, M., Chiti, H., Shoghli, A., Biglari, S., Parsamanesh, N., & Esmaeilzadeh, A. (2021). COVID‐19: Virology, biology and novel laboratory diagnosis. The Journal of Gene Medicine, 23(2). https://doi.org/10.1002/jgm.3303 DOI: https://doi.org/10.1002/jgm.3303

Palaiodimou, L., Stefanou, M., Katsanos, A. H., Fragkou, P. C., Papadopoulou, M., Moschovos, C., Michopoulos, I., Kokotis, P., Bakirtzis, C., Naska, A., Vassilakopoulos, T. I., Chroni, E., Tsiodras, S., & Tsivgoulis, G. (2021). Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis. European Journal of Neurology, 28(10), 3517–3529. https://doi.org/10.1111/ene.14860 DOI: https://doi.org/10.1111/ene.14860

Paliwal, V. K., Garg, R. K., Gupta, A., & Tejan, N. (2020). Neuromuscular presentations in patients with COVID-19. Neurological Sciences, 41(11), 3039–3056. https://doi.org/10.1007/s10072-020-04708-8 DOI: https://doi.org/10.1007/s10072-020-04708-8

Patnaik, U. J. (2021). Review article on COVID-19 and Guillain-Barré syndrome. Frontiers in Bioscience, 13(1), 97. https://doi.org/10.52586/s555 DOI: https://doi.org/10.52586/S555

Peña, S. L., Bello Quezada, M. E., & Segura Lemus, V. (2021). Manifestaciones Neurológicas y COVID-19. Alerta, Revista Científica Del Instituto Nacional de Salud, 4(2), 69–80. https://doi.org/10.5377/alerta.v4i2.9772 DOI: https://doi.org/10.5377/alerta.v4i2.9772

Sansone, P., Giaccari, L. G., Aurilio, C., Coppolino, F., Esposito, V., Fiore, M., Paladini, A., Passavanti, M. B., Pota, V., & Pace, M. C. (2021). Post-Infectious Guillain–Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review. Life, 11(2), 167. https://doi.org/10.3390/life11020167 DOI: https://doi.org/10.3390/life11020167

Sheikh, A. B., Chourasia, P. K., Javed, N., Chourasia, M. K., Suriya, S. S., Upadhyay, S., Ijaz, F., Pal, S., Moghimi, N., & Shekhar, R. (2021). Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review. Journal of Neuroimmunology, 355, 577577. https://doi.org/10.1016/j.jneuroim.2021.577577 DOI: https://doi.org/10.1016/j.jneuroim.2021.577577

Shoraka, S., Ferreira, M. L. B., Mohebbi, S. R., & Ghaemi, A. (2021). SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.674922 DOI: https://doi.org/10.3389/fimmu.2021.674922

Tawakul, A. A., Al-Doboke, A. W., Altayyar, S. A., Alsulami, S. A., Alfahmi, A. M., & Nooh, R. T. (2021). Guillain-Barré Syndrome in the COVID-19 Pandemic. Neurology International, 14(1), 34–48. https://doi.org/10.3390/neurolint14010003 DOI: https://doi.org/10.3390/neurolint14010003

Uncini, A., Vallat, J.-M., & Jacobs, B. C. (2020). Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. Journal of Neurology, Neurosurgery & Psychiatry, 91(10), 1105–1110. https://doi.org/10.1136/jnnp-2020-324491 DOI: https://doi.org/10.1136/jnnp-2020-324491

Velavan, T. P., & Meyer, C. G. (2020). The COVID‐19 epidemic. Tropical Medicine & International Health, 25(3), 278–280. https://doi.org/10.1111/tmi.13383 DOI: https://doi.org/10.1111/tmi.13383